| Literature DB >> 33072431 |
Natalie C Frayer1, Yeonsoo Kim2.
Abstract
OBJECTIVE: This paper evaluates the association between caffeine consumption during pregnancy and overweight or obesity in the offspring.Entities:
Keywords: Caffeine intake; Childhood; Obesity; Overweight; Pregnancy; Prenatal; Serum paraxanthine; Systematic review
Year: 2020 PMID: 33072431 PMCID: PMC7545400 DOI: 10.21106/ijma.387
Source DB: PubMed Journal: Int J MCH AIDS ISSN: 2161-864X
Figure 1PRISMA flow diagram
Summary of Studies Included in the Systematic Review
| Authors/Cohort | Time frame of follow- up | How Caffeine intake was obtained | Sources of Caffeine | Measurement of Caffeine (mg) | Main results (95% CI) |
|---|---|---|---|---|---|
| Voerman, et al, 2016. | From birth to 6 years | Postal Questionnaires during 1st, 2nd and 3rd trimesters | Coffee, Tea | Each unit of caffeine based on 1 cup of caffeinated coffee ~90mg=1unit | |
| Voerman E, et al, 2019. | 10 years old | Postal Questionnaires during 1st, 2nd and 3rd trimesters | Coffee, Tea | Each unit of caffeine based on 1 cup of caffeinated coffee ~90mg=1unit | |
| Papadopoulou E, et al, 2018. | 6, 18, 36 months and 5, 7 and 8 years. | FFQ during first 4-5 months of gestation | Coffee, black tea, caffeinated soft drinks, energy drinks, chocolate, chocolate milk and sandwich spreads, desserts, cakes and sweets with cocoa. | Caffeine in mg/d Low (0-49) Avg (50-199) High(200-299) Very High (≥300) | |
| Li DK, et al, 2015. | 15 years | In-person interview in first or very early second trimester. | Coffee (caffeinated or decaf) Tea (caffeinated or decaf), caffeinated soda, hot chocolate. | For every 150ml of a beverage ~5oz. Coffee:100mg Decaf Coffee: 2mg Tea: 39mg Decaf Tea: N/A Soda: 15mg Hot Choc: 2mg | Maternal caffeine intake overall during pregnancy has an 87% risk of their children having obesity using BMI-for-age criteria OR 1.87 (95% CI: 1.12, 3.12) (P |
| Chen L, et al, 2019. | 5 and 9 years old | FFQ in first trimester | Coffee, tea, soft drinks, chocolate containing food and beverages | Caffeine divided into groups depending on intake reported in FFQ. All in mg/day <50, 50-<100, 100 to <200 and ≥200/day. | |
| Santos de Medeiros T, et al, 2017. | 3 and 6 months of age | FFQ 7 days post-partum | Caffeine from coffee only | Caffeine in mg by converting serving sizes as needed and using U.S nutritional tables. | Mothers who had caffeine during pregnancy had children with increased skinfold measurements at 3 months 0.0015 (0.000, 0.029) (p<0.047). No significant association with measurements at 6 months. |
| Barr and Streissguth, 1991. | Birth to 7 years of age | Self-reported consumption using quantity-frequency-variability interview | Coffee, tea, cola, chocolate candy and chocolate milk | 27 mg for non-herbal tea, 112, 74 or 66 mg per cup of dripped, percolated or instant coffee, 10mg choc milk, 31mg soft drink and 20mg for 4oz chocolate bar | No association was found with prenatal caffeine exposure and birthweight, birth length, or head circumference. |
| Klebanoff and Keim, 2015. | 4 and 7 years of age | Serum paraxanthine collected at registration and every 8 weeks during pregnancy, at delivery and 6 weeks post-partum | Caffeine intake in general – no specific source as the caffeine metabolite was being measured | n/a | No association between serum paraxanthine levels during pregnancy and childhood overweight or obesity. |
Results compared to low caffeine intake or no caffeine intake
BMI identified by using International Obesity Task Force Criteria Abbreviations: FFQ=food frequency questionnaire, BMI=Body Mass index
Demographic Information of Mothers
| Authors, year, place of cohort. | Number of Subjects | Mean age (yr) | Pre-pregnancy BMI | Ethnicity | Education level | Smoked during pregnancy (yes) | Parity |
|---|---|---|---|---|---|---|---|
| Voerman, et al, | 7,857 mothers in analysis. 5,562 children at follow-up | 30.4 | 22.6 | 58.5% of European descent | 5.9% primary 43.3% secondary 50.8% higher | 18.6% | 43.6% multiparous |
| Voerman E, et al, | 4770 mothers with children at follow-up | 31.2 | 22.6 | 65.8% European descent | 7.4% primary 42.2% secondary 50.4% higher | 24.3% | 41.2% multiparous |
| Papadopoulou E, et al, | 50,943 mother-child pairs | <20= < 1% 20-29=44.6% ≥30=54.5% | <18.5=2% 18.5-24.9=66.2% 25-29.9=21.7% ≥30=9% | n/a | < 13 years=29.2% 13-16 years=43.9% >16 years=26.7 | 7% | 46% multiparous |
| Li DK, et al, | 661 children | <25=67.9% ≥25=32% | White=34.4% Black=6% Hispanic=23.5% Asian/Pacific Islander=30.8% Other=4% | <College=56.7% College degree=28.6% Graduate School=14.4% | 9.9% | 57% multiparous | |
| Chen L, et al, | 558 mother-child pairs | 30.8±5.7 | 23.7±3.8 | n/a | Below tertiary=48% Tertiary or above=52% | 26% | 57% multiparous |
| Santos de Medeiros T, et al, | 272 mother-child pairs | 26.2±6.7 | 24.4±6.6 | White=60.3% | Median: 10 years | 25% | 58.8% multiparous |
| Barr and Streissguth, | 1529 mothers | 13-16=2% 17-24=33% 25-32=59% 33-40=6% >40=<1% | n/a | White=86% Black=9% Other=5% | <High school=11% High School Grad=28% Some College=29% College Grad=25% Grad School=7% | n/a | 56% multiparous |
| Klebanoff and Keim, | 1900 mothers | <20=14.5% 20-24=38.6% 25-29=23.8% 30-34=13.7% ≥35=9% | n/a | White=68.5 Other=31.4 | <12 years=40.9% 12 years=39.7% >12 years=19.2% | 41% | n/a |
Age at Delivery
Of the 1529 mothers in the cohort, only 500 children were selected for measurements at follow up.
Of the 18=1900 mothers that provided ≥26 weeks serum, only 1635 children were included in the final follow up
Figure 2Risk of Bias in Individual Studies26
quality assessment of observational cohort and cross-sectional studies
| Reference | Possible conflict of interest reported | Total quality score | Criteria not met |
|---|---|---|---|
| Voerman, et al, | No | 11 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Voerman E, et al, | No | 11 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Papadopoulou E, et al, | No | 10 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Li DK, et al, | No | 11 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Chen L, et al, | No | 10 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Santos de Medeiros T, et al, | No | 11 | Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome? No |
| Barr and Streissguth, | Not stated | 11 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
| Klebanoff and Keim, | Not stated | 12 | Was a sample size justification, power description, or variance and effect estimates provided? Not recorded. |
Total Quality Score determined by National Heart, Lung and Blood Institute’s Study Quality Assessment Tools Scoring criteria obtained from the National Heart, Lung and Blood Institute’s Quality Assessment of Observational Cohort and Cross-Sectional Studies Scoring criteria obtained from the National Heart, Lung and Blood Institute’s Quality Assessment with Maximum Quality Score of 14